{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:29:25Z","timestamp":1790861365637,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.dld.2022.12.010","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T08:02:10Z","timestamp":1672473730000},"page":"1318-1327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"55","author":[{"given":"Jakub","family":"Gazda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Drazilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Gazda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Janicko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Koky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Macej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jarcuska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2022.12.010_bib0001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.12.010_bib0005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.010_bib0006","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0007","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.010_bib0008","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.010_bib0009","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0010","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.medcli.2018.08.002","article-title":"An\u00e1lisis de los \u00edndices predictores de respuesta al tratamiento con \u00e1cido ursodeoxic\u00f3lico en pacientes con colangitis biliar primaria","volume":"152","author":"Brunet","year":"2019","journal-title":"Med Clin"},{"key":"10.1016\/j.dld.2022.12.010_bib0012","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/ctg.2017.23","article-title":"Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid","volume":"8","author":"Cheung","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0013","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.14309\/ajg.0000000000000290","article-title":"Validation of risk scoring systems in ursodeoxycholic acid\u2013treated patients with primary biliary cholangitis","volume":"114","author":"Efe","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0014","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00365521.2019.1606931","article-title":"Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study","volume":"54","author":"\u00d6rnolfsson","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0016","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.010_bib0017","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.12.010_bib0018","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.12.010_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.dld.2022.12.010_bib0022","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint\u2014Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.dld.2022.12.010_bib0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.dld.2022.12.010_bib0024","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1872-034X.2009.00550.x","article-title":"Portal hypertension in primary biliary cirrhosis (PBC): a reversible condition? Yes, but not in all UDCA treated patients","volume":"39","author":"Huet","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2022.12.010_bib0026","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.010_bib0027","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0028","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2022.12.010_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/00365513.2012.731709","article-title":"Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid","volume":"73","author":"Huang","year":"2013","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.dld.2022.12.010_bib0030","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0031","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.010_bib0032","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/jgh.12938","article-title":"New simple prognostic score for primary biliary cirrhosis: albumin-bilirubin score","volume":"30","author":"Chan","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0033","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.010_bib0034","doi-asserted-by":"crossref","first-page":"714","DOI":"10.5009\/gnl18271","article-title":"Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio","volume":"12","author":"Yoo","year":"2018","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2022.12.010_bib0035","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0036","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.010_bib0037","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0038","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.010_bib0039","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/jcm8081258","article-title":"Prediction of transplant-free survival through albumin-bilirubin score in primary biliary cholangitis","volume":"8","author":"Fujita","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2022.12.010_bib0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep4.1186","article-title":"External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid","volume":"2","author":"Cheung","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2022.12.010_bib0041","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00535-013-0903-1","article-title":"Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients","volume":"49","author":"Lammert","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0042","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.14309\/ajg.0000000000001285","article-title":"A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis","volume":"116","author":"Goet","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.010_bib0043","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejim.2017.05.006","article-title":"Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece","volume":"42","author":"Gatselis","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.dld.2022.12.010_bib0044","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D'Amato","year":"2021","journal-title":"JHEP Reports"},{"key":"10.1016\/j.dld.2022.12.010_bib0045","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.12.010_bib0046","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.010_bib0047","article-title":"A validation study of the UDCA response score in a Japanese PBC cohort","volume":"14","author":"Minami","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2022.12.010_bib0048","first-page":"2021","article-title":"External validation of UDCA response score in slovak and croatian patients with primary biliary cholangitis","author":"Gazda","year":"2021","journal-title":"Can J Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822008349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822008349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:24:17Z","timestamp":1761625457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822008349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1590865822008349"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.12.010","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}